You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
SBC: HARLINGENE LIFE SCIENCES LLC Topic: NIAIDHepatoselective Dihydroquinolizinone (HS-HS-DHQ) Molecules for Treatment and Preventionof Hepatitis A Virus Infection ABSTRACT This is a Phase I proposal to develop Harlingene’s hepatoselective dihydroquinolizinones (HS- DHQs) for treatment and prevention of hepatitis A virus (HAV) infection. This will be the first antiviral therapy to treat HAV infection, which, despite vaccines to prevent dise ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Epigenetic Modifiers to treat Photoreceptor Degenerations
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract:The overall goal of Skyran Biologics is to develop powerful topical therapeutics to combat retinal degenerative diseases. In the course of our studies on epigenetic regulation of retinal development we have defined ways in which histone modifications can lock genes encoding these mechanisms into inactive, condensed chromatin. We found a number of drugs that partially reverse chromatin con ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Restoration of Muscular Function Following Direct Muscle Neurotization
SBC: Renerva, LLC Topic: 107Summary/Abstract More than 500,000 surgical procedures are performed annually in the US to address peripheral nerve injury (PNI), at a cost of more than $1.1B. PNI and their sequelae affect more than 20 million Americans, with total economic impacts in excess of $150B annually. Despite advances in microsurgical techniques and the inherent ability of the peripheral nervous system to regenerate, few ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Synergize a novel homologous recombination inhibitor with DNA damagingagents in TNBC
SBC: CREEGH PHARMACEUTICALS INC Topic: NCI15-20% of all breast cancers are triple negative, being devoid of the three receptors that classify and define treatment strategies for most mammary cancers: estrogen receptor (ER), progesterone receptor (PR) and ERB2 (also known as HER2). Because of this, no targeted therapies are available for TNBC patients. This poses a destitute situation, as TNBC is an aggressive cancer that disproportionally ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
SBC: DUO ONCOLOGY INC. Topic: O1Abstract Pancreatic cancer (PC) has an annual worldwide incidence of more than 495,000 cases and an annual mortality rate of almost 460,000 cases. Most patients are diagnosed late and cannot undergo resection and therefore rely on pharmacotherapy to extend their lives. Current therapies offer only limited benefit due in large part to the dense stroma tissue that surrounds and protects the tumor. D ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Structurally engineered N-acyl amino acids for the treatment of NASH
SBC: FURANICA, INC. Topic: 300Project Summary Nonalcoholic steatohepatitis (NASH) occurs when excessive amounts of fat build up in the liver, damaging hepatocytes and causing inflammation. The progression of the disease further leads to fibrosis, hepatocellular carcinoma, and liver failure. After numerous failures in clinical trials with single-agent therapies, the therapeutic approach has gradually shifted toward using combin ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Opioid-Sparing Non-Surgical, Bioresorbable Nerve Stimulator for Pain Relief
SBC: VANISH THERAPEUTICS INC Topic: NINDSProject Summary The lack of effective pain treatments has catalyzed the opioid epidemic in America, causing an estimated 93,000 deaths in 2020, calling for more effective and non-opioid based management. One alternative pain treatment is via nerve stimulators, which are devices placed near a peripheral nerve or on the spinal cord and use electrical signals to modulate the perception of pain. Most ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Treatment of Inflammatory Complications of Respiratory Infection
SBC: Respana Therapeutics, Inc Topic: NIAIDAbstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SIRPant Technology for anti-Cancer Immunity
SBC: SIRPANT IMMUNOTHERAPEUTICS INC Topic: 102PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
SBC: Trevarx Biomedical, Inc. Topic: 102ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health